Q2 EPS Estimate for ORIC Pharmaceuticals Reduced by Analyst

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) – Stock analysts at HC Wainwright lowered their Q2 2025 earnings per share estimates for shares of ORIC Pharmaceuticals in a report issued on Monday, January 13th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.55) per share for the quarter, down from their previous forecast of ($0.54). HC Wainwright currently has a “Buy” rating and a $21.00 price target on the stock. The consensus estimate for ORIC Pharmaceuticals’ current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for ORIC Pharmaceuticals’ Q3 2025 earnings at ($0.57) EPS.

Other analysts have also issued research reports about the stock. Wells Fargo & Company assumed coverage on shares of ORIC Pharmaceuticals in a research note on Thursday, October 31st. They issued an “overweight” rating and a $20.00 price objective on the stock. Wedbush reaffirmed an “outperform” rating and set a $20.00 price target on shares of ORIC Pharmaceuticals in a research report on Monday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of ORIC Pharmaceuticals in a report on Tuesday. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, ORIC Pharmaceuticals currently has an average rating of “Buy” and an average target price of $18.29.

ORIC Pharmaceuticals Trading Down 7.6 %

Shares of NASDAQ:ORIC opened at $10.04 on Thursday. ORIC Pharmaceuticals has a twelve month low of $6.33 and a twelve month high of $16.65. The company has a market cap of $708.52 million, a PE ratio of -5.58 and a beta of 1.18. The company’s 50 day moving average is $9.01 and its 200 day moving average is $9.46.

ORIC Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.01).

Institutional Trading of ORIC Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Alkeon Capital Management LLC lifted its stake in ORIC Pharmaceuticals by 2.6% in the 3rd quarter. Alkeon Capital Management LLC now owns 3,904,096 shares of the company’s stock valued at $40,017,000 after buying an additional 100,000 shares in the last quarter. ArrowMark Colorado Holdings LLC raised its holdings in shares of ORIC Pharmaceuticals by 6.4% during the third quarter. ArrowMark Colorado Holdings LLC now owns 1,354,508 shares of the company’s stock valued at $13,884,000 after acquiring an additional 80,986 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of ORIC Pharmaceuticals by 4.2% in the third quarter. Geode Capital Management LLC now owns 1,273,513 shares of the company’s stock valued at $13,056,000 after acquiring an additional 50,821 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of ORIC Pharmaceuticals by 26.1% in the third quarter. Franklin Resources Inc. now owns 950,459 shares of the company’s stock worth $9,067,000 after acquiring an additional 196,804 shares during the last quarter. Finally, Millennium Management LLC increased its position in shares of ORIC Pharmaceuticals by 297.4% during the second quarter. Millennium Management LLC now owns 782,299 shares of the company’s stock worth $5,531,000 after purchasing an additional 585,447 shares in the last quarter. Institutional investors and hedge funds own 95.05% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Dominic Piscitelli sold 8,851 shares of ORIC Pharmaceuticals stock in a transaction on Monday, December 16th. The shares were sold at an average price of $8.28, for a total value of $73,286.28. Following the sale, the chief financial officer now owns 106,764 shares of the company’s stock, valued at approximately $884,005.92. This trade represents a 7.66 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jacob Chacko sold 24,660 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $8.28, for a total transaction of $204,184.80. Following the transaction, the chief executive officer now owns 778,648 shares of the company’s stock, valued at $6,447,205.44. This represents a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 42,361 shares of company stock worth $350,749. Company insiders own 5.55% of the company’s stock.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.